These trials were led mainly by Targeted Genetics (now AmpliPhi Biosciences) and used serotype 2 (AAV2).65 Initial single-dose phase I trials demonstrated that virus administration to the CF airways was safe, but provided little opportunity to assess the efficiency of vector-specific CFTR expression. Here, CFTR is linked to cystic fibrosis.